Anti-PSMD13 / 26S proteasome non-ATPase regulatory subunit 13

Adding 0.2 ml of distilled water will yield a concentration of 500 ug/ml. PSMD13 antibody detects 26S proteasome non-ATPase regulatory subunit 13, encoded by the PSMD13 gene on chromosome 11q22.3. PSMD13 antibody is commonly applied in studies of protein degradation, ubiquitin-proteasome system regulation, and cellular quality control. PSMD13, also known as RPN9, is a non-ATPase subunit of the 19S regulatory particle of the 26S proteasome. It contributes to substrate recognition, deubiquitination, and assembly of the proteasome complex. Expression is ubiquitous, reflecting its essential role in protein turnover and cellular homeostasis.Structurally, PSMD13 is part of the base subcomplex of the 19S regulatory particle. It contains proteasome-specific domains that mediate interaction with ubiquitinated substrates and other proteasome subunits. PSMD13 is critical for correct assembly of the 19S complex, ensuring proper substrate unfolding and delivery to the 20S catalytic core. Its interactions with ATPases and deubiquitinases highlight its importance in coupling recognition and processing steps.Functionally, PSMD13 regulates degradation of misfolded, damaged, or regulatory proteins by the proteasome. By supporting substrate recruitment and unfolding, it maintains protein homeostasis and regulates processes including cell cycle progression, apoptosis, and stress responses. Knockdown of PSMD13 impairs proteasome activity, leading to accumulation of ubiquitinated proteins and cellular stress. Researchers use PSMD13 antibody to study proteasome biology, protein quality control, and pathways involving ubiquitination.Clinically, proteasome dysfunction is linked to neurodegeneration, cancer, and immune disorders. PSMD13 expression changes have been observed in Alzheimer's disease and Parkinson's disease, where proteostasis failure contributes to pathology. In cancer, altered proteasome activity supports tumor survival and resistance to stress. PSMD13 has been studied as a biomarker for disease states involving proteasome regulation. Therapeutic strategies targeting the proteasome, such as bortezomib, indirectly involve PSMD13 function by disrupting regulatory particle activity. NSJ Bioreagents provides PSMD13 antibody to facilitate proteasome and disease-related studies.Experimentally, PSMD13 antibody is used in western blotting to detect the ~42 kDa protein, in immunofluorescence to study localization within proteasome-rich regions, and in immunoprecipitation to isolate 26S proteasomes. Immunohistochemistry with PSMD13 antibody allows evaluation of expression in tissues under stress or disease conditions.